FDA to remove black box warnings on hormone therapy for menopause Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31.

NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism

Pressed by Sen. Bernie Sanders (I-VT), NIH Director Jay Bhattacharya acknowledged that he is not aware of any study pointing to a causal link between vaccines and autism.

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

NIH announced Jan. 29 that “Basic Experimental Studies Involving Humans,” also called BESH, will no longer be considered clinical trials and will therefore no longer be subject to the requirements under the NIH definition of a clinical trial, including registration and reporting requirements in ClinicalTrials.gov.

FDA debuts precheck manufacturing program to boost domestic drug development

FDA has launched a venture in onshoring domestic drug development called the Precheck Pilot Program.

February 06, 2026

Vol.52 No.05

By Claire Marie Porter

Drugs & Targets

FDA issues a boxed warning for capecitabine and fluorouracil on risks associated with DPD deficiency

FDA announced recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase deficiency.

February 06, 2026

Vol.52 No.05

Cancer Policy

FDA delays drug reviews in new voucher program amid safety, efficacy concerns

The reviews of two drugs granted priority review via FDA’s new priority voucher program, Commissioner’s National Priority Voucher (CNPV) Pilot Program, have been delayed.

January 30, 2026

Vol.52 No.04

By Claire Marie Porter

FDA to remove black box warnings on hormone therapy for menopause

Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence

YOU MAY BE INTERESTED IN

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

FDA debuts precheck manufacturing program to boost domestic drug development

FDA issues a boxed warning for capecitabine and fluorouracil on risks associated with DPD deficiency

FDA delays drug reviews in new voucher program amid safety, efficacy concerns

Renew today!

Subscriber content

Never miss an issue!

Login

FDA to remove black box warnings on hormone therapy for menopause

Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence

YOU MAY BE INTERESTED IN

After a brief government shutdown, FY26 funding bill is signed into lawNIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

FDA debuts precheck manufacturing program to boost domestic drug development

FDA issues a boxed warning for capecitabine and fluorouracil on risks associated with DPD deficiency

FDA delays drug reviews in new voucher program amid safety, efficacy concerns

Never miss an issue!

Login

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored